CA3029864C - Administration de gene a mediation par aav2 de sfasl comme therapie neuroprotectrice dans le glaucome - Google Patents

Administration de gene a mediation par aav2 de sfasl comme therapie neuroprotectrice dans le glaucome

Info

Publication number
CA3029864C
CA3029864C CA3029864A CA3029864A CA3029864C CA 3029864 C CA3029864 C CA 3029864C CA 3029864 A CA3029864 A CA 3029864A CA 3029864 A CA3029864 A CA 3029864A CA 3029864 C CA3029864 C CA 3029864C
Authority
CA
Canada
Prior art keywords
sfasl
raav
subject
nucleic acid
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3029864A
Other languages
English (en)
Other versions
CA3029864A1 (fr
Inventor
Ann Marshak-Rothstein
Meredith Gregory-Ksander
Bruce Ksander
Original Assignee
Massachusetts Eye and Ear Infirmary
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye and Ear Infirmary, University of Massachusetts Amherst filed Critical Massachusetts Eye and Ear Infirmary
Priority claimed from PCT/US2017/040735 external-priority patent/WO2018009553A1/fr
Publication of CA3029864A1 publication Critical patent/CA3029864A1/fr
Application granted granted Critical
Publication of CA3029864C publication Critical patent/CA3029864C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Méthodes de traitement du glaucome et/ou d'états inflammatoires dépendant du ligand de Fas chez un sujet à l'aide du ligand de Fas soluble (sFasL) ou d'un fragment de celui-ci, qui peuvent être une administration médiée par rAAV de sFasL ou d'un fragment de celui-ci à un sujet.
CA3029864A 2016-07-05 2017-07-05 Administration de gene a mediation par aav2 de sfasl comme therapie neuroprotectrice dans le glaucome Active CA3029864C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662358541P 2016-07-05 2016-07-05
US62/358,541 2016-07-05
US201762511629P 2017-05-26 2017-05-26
US62/511,629 2017-05-26
PCT/US2017/040735 WO2018009553A1 (fr) 2016-07-05 2017-07-05 Administration de gène à médiation par aav2 de sfasl comme thérapie neuroprotectrice dans le glaucome

Publications (2)

Publication Number Publication Date
CA3029864A1 CA3029864A1 (fr) 2018-01-11
CA3029864C true CA3029864C (fr) 2025-11-18

Family

ID=

Similar Documents

Publication Publication Date Title
US20250001015A1 (en) Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
ES2836258T3 (es) Construcciones de vectores virales adenoasociados de GLUT1 recombinante y métodos relacionados para restaurar la expresión de GLUT1
US12454702B2 (en) Minigene therapy
US20180214576A1 (en) Transgenic expression of dnasei in vivo delivered by an adeno-associated virus vector
US20260022154A1 (en) Gene therapies for stargardt disease (abca4)
US20230056226A1 (en) Compositions and methods for treating neurofibromatic disorders
JP2021520811A (ja) ヘキソサミニダーゼアルファおよびベータサブユニットをコードしているバイシストロニックａａｖベクターならびにその使用
US12570997B2 (en) Factor H vectors and uses thereof
US20240207450A1 (en) Gene therapies for stargardt disease (abca4)
CA3029864C (fr) Administration de gene a mediation par aav2 de sfasl comme therapie neuroprotectrice dans le glaucome
US20210222167A1 (en) Slc2a1 lncrna as a biologic and related treatments and methods
US20240124893A1 (en) Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy
US20250360226A1 (en) Oxr1 gene therapy
Fehrman Feasibility of Large Transgene Delivery to the Mouse Retina: Eyeing the Potential for Gene Therapy Applications